Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2
Authors:
- Mushtaq HussainMushtaq Hussain
- Anusha AmanullahAAAnusha Amanullah
- Ayesha AslamAyesha Aslam
- Fozia RazaFRFozia Raza
- Shabana ArzooSAShabana Arzoo
- Iffat Waqar QureshiIQIffat Waqar Qureshi
- Humera WaheedHWHumera Waheed
- Nusrat JabeenNJNusrat Jabeen
- Sanya ShabbirSSSanya Shabbir
- Muneeba Ahsan SayeedMSMuneeba Ahsan Sayeed
- Saeed QuraishySQSaeed Quraishy
Open Access
Abstract
To effectively counter the evolving threat of SARS-CoV-2 variants, modifications and/or redesigning of mRNA vaccine construct are essentially required. Herein, the design and immunoinformatic assessment of a candidate novel mRNA vaccine construct, DOW-21, are discussed. Briefly, immunologically important domains, N-terminal domain (NTD) and receptor binding domain (RBD), of the spike protein of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) were assessed for sequence, structure, and epitope variations. Based on the assessment, a novel hypothetical NTD (h-NTD) and RBD (h-RBD) were designed to hold all overlapping immune escape variations. The construct sequence was then developed, where h-NTD and h-RBD were intervened by 10-mer gly-ala repeat and the terminals were flanked by regulatory sequences for better intracellular transportation and expression of the coding regions. The protein encoded by the construct holds structural attributes (RMSD NTD: 0.42 Å; RMSD RBD: 0.15 Å) found in the respective domains of SARS-CoV-2 immune escape variants. In addition, it provides coverage to the immunogenic sites of the respective domains found in SARS-CoV-2 variants. Later, the nucleotide sequence of the construct was optimized for GC ratio (56%) and microRNA binding sites to ensure smooth translation. Post-injection antibody titer was also predicted (~12000 AU) to be robust. In summary, the construct proposed in this study could potentially provide broad spectrum coverage in relation to SARS-CoV-2 immune escape variants.Keywords
This publication has 80 references indexed in Scilit:
- Reliable B Cell Epitope Predictions: Impacts of Method Development and Improved BenchmarkingPLOS Computational Biology, 2012
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- Mammalian microRNAs predominantly act to decrease target mRNA levelsNature, 2010
- Computational Immunology Meets Bioinformatics: The Use of Prediction Tools for Molecular Binding in the Simulation of the Immune SystemPLOS ONE, 2010
- Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapyClinical Immunology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- The Vienna RNA WebsuiteNucleic Acids Research, 2008
- Clustal W and Clustal X version 2.0Bioinformatics, 2007
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Production of soluble MHC class II proteins with covalently bound single peptidesNature, 1994